Abstract
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the production of antiphospholipid antibodies (aPL) resulting in clinical complications such as blood clots and pregnancy complications. The purpose of this chapter is to provide a general review of APS for patients and those who are interested in learning more about aPL/APS. Detailed information about aPL-related pregnancy problems can be found in Chapter 20.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abreu MM, Danowski A, Wahl DG, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14:401–14.
Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, de Jesus GR, Erkan D, on behalf of APS ACTION. The estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis. Arthritis Care Res (Hoboken). 2013;65:1869–73.
Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody–positive patients: where do we stand? Curr Rheumatol Rep. 2011;13:59–69.
Bertolaccini ML, Amengual O, Andreoli L, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014;13:917–30.
Canaud G1, Bienaimé F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014 Jul 24;371:303–12.
Cervera R, Rodríguez-Pintó I, Colafrancesco C, et al. 14th International Congress on Antiphospholipid Antibodies Task Force on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev. 2014;13:699–707.
de Jesus GR, Agmon-Levin N, Andrade CA, et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev. 2014;13:795–813.
Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: update diagnostic algorithms. Autoimmun Rev. 2010;10:74–9.
Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13:685–96.
Erkan D, Vega J, Ramon G, et al. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65:464–71.
Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368:1033–44.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb. 2016;4:295–306.
Ruiz-Irastirza G, Cuadrado M, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20:206–18.
Unlu O, Zuily S, Erkan D.The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016;3:75–84.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Erkan, D., Unlu, O., Lally, L., Lockshin, M.D. (2017). Antiphospholipid Syndrome: What Should Patients Know?. In: Erkan, D., Lockshin, M. (eds) Antiphospholipid Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-319-55442-6_19
Download citation
DOI: https://doi.org/10.1007/978-3-319-55442-6_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-55440-2
Online ISBN: 978-3-319-55442-6
eBook Packages: MedicineMedicine (R0)